Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma-Reference-Cited by-同舟云学术

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Published:2018-01-25 Issue:4 Volume:378 Page:331-344
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Connors Joseph M.¹,Jurczak Wojciech¹,Straus David J.¹,Ansell Stephen M.¹,Kim Won S.¹,Gallamini Andrea¹,Younes Anas¹,Alekseev Sergey¹,Illés Árpád¹,Picardi Marco¹,Lech-Maranda Ewa¹,Oki Yasuhiro¹,Feldman Tatyana¹,Smolewski Piotr¹,Savage Kerry J.¹,Bartlett Nancy L.¹,Walewski Jan¹,Chen Robert¹,Ramchandren Radhakrishnan¹,Zinzani Pier L.¹,Cunningham David¹,Rosta Andras¹,Josephson Neil C.¹,Song Eric¹,Sachs Jessica¹,Liu Rachael¹,Jolin Hina A.¹,Huebner Dirk¹,Radford John¹

Affiliation:

1. From the University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada (J.M.C., K.J.S.); the Department of Hematology, Jagiellonian University, Krakow (W.J.), the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw (E.L.-M.), the Department of Hematology and Transfusion Medicine, Center of Postgraduate Medical Education, Warsaw (E.L.-M.), the Department of Experimental Hematology, Medical...

Funder

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Seattle Genetics, Inc., Bothell, WA, USA

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1708984

Cited by 537 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03

2. Antibody drug conjugates in older patients: State of the art;Critical Reviews in Oncology/Hematology;2024-01

3. Safety and Efficacy of CD30.CAR-T Cells as Consolidation Post Autologous Transplant in High-Risk CD30 Lymphoma;2024

4. Antibody based therapies in Hodgkin lymphoma;Cancer Treatment Reviews;2024-01

5. Harnessing multi-source data for individualized care in Hodgkin Lymphoma;Blood Reviews;2024-01